(e)

At meetings on

November 16-17, 2016, the Board of Directors (the Board) of Mallinckrodt plc (the Company) approved, with respect to the Companys President and Chief Executive Officer, and the Human Resources and Compensation Committee (the Committee) of the Board approved, with respect to the Companys other named executive officers, certain compensation related actions. With respect to Mark C. Trudeau, President and Chief Executive Officer, the Board increased his annual base salary, effective December 26, 2016, from $1,000,000 to $1,050,000. With respect to Hugh ONeill, Executive Vice President and President, Autoimmune and Rare Diseases, the Committee increased his annual base salary, effective December 26, 2016, from $475,000 to $550,000. With respect to Frank Scholz, Ex ecutive Vice President of Global Operations and President, Specialty Generics, the Committee increased his annual base salary, effective October 3, 2016, from $460,000 to $500,000.

Also, the Board, with respect to the President and Chief Executive Officer, and the Committee, with respect to the other named executive officers, determined the target grant date dollar value of long-term incentive compensation for fiscal 2017, which includes the annual long-term incentive awards (the Annual Awards) and special retention awards (the Retention Awards) which are intended to ensure continuity among the Companys executives, which will be granted on January 3, 2017 (the Grant Date). The Annual Awards include the period from October 1, 2016 to December 30, 2016 (i.e., the transition period in connection with the previously announced change in the Companys fiscal year end) and, as a result, are approximately 25% larger to account for this additional time period. The table below sets forth the target grant date fair value awarded to each of the named executive officers with respect to their Annual Awards and Retentions Awards:

Name and Title

Annual Award

Retention Award

Mark C. Trudeau

President and Chief Executive Officer

$

11,500,000

$

Matthew K. Harbaugh

Executive Vice President and Chief Financial Officer

3,438,000

2,335,000

Hugh ONeill

Executive Vice President and President, Autoimmune and Rare Diseases

2,500,000

2,000,000

Frank Scholz

Executive Vice President of Global Operations and President, Specialty Generics

2,500,000

2,000,000

Gary M. Phillips

Executive Vice President and Chief Strategy Officer

2,000,000

1,360,000

The dollar value awarded to each named executive officer for the Annual Awards will be allocated between the long-term incentive vehicles as follows:

40% of the target grant date fair value will be allocated to performance shares (PSUs) with performance-based vesting over a three-year vesting period (December 31, 2016 up to and including December 27, 2019) based on total return of shareholders against a defined peer group (weighted 50%) and Net Revenue Compound Annual Growth Rate (Net Revenue CAGR). For PSU purposes, Net Revenue CAGR is calculated for the performance period (December 31, 2016 - December 27, 2019) using non-GAAP Net Sales Revenue where GAAP Net Sales Revenue has been adjusted to exclude the impact of both acquisitions and divestitures during the performance period. The actual number of PSUs will be determined on the Grant Date by taking the dollar value allocated to PSUs and dividing such amount by the grant date fair value of a PSU using, for 50% of the value, a Monte Carlo simulation model and for the remaining 50% of the value, the closing price of the Companys ordinary shares on the Grant Date. Depending on the Companys performance during the performance period, the named executive officer is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0% to 200%, of the award granted.

40% of the target grant date fair value will be allocated to non-qualified stock options vesting ratably over a four-year period on the anniversary of the Grant Date. The actual number of stock options will be determined on the Grant Date by taking the dollar value allocated to stock options and dividing such amount by the grant date fair value of an option using a Black-Scholes valuation model; and

20% of the target grant date fair value will be allocated to restricted stock units (RSUs) vesting ratably over a four-year period on the anniversary of the Grant Date. The actual number of RSUs will be determined on the Grant Date by taking the dollar value allocated to RSUs and dividing such amount by Fair Market Value (as defined in the Mallinckrodt Pharmaceuticals Stock and Incentive Plan) of the Companys ordinary shares on the Grant Date.

The dollar value awarded to each named executive officer for the Retention Awards will be allocated between the long-term incentive vehicles as follows:

25% of the target grant date fair value will be allocated to PSUs with performance-based vesting over a three-year vesting period (December 30, 2016 up to and including December 27, 2019) based on Net Revenue CAGR and 25% of the target grant date fair value will be allocated to PSUs with performance-based vesting over a three-year vesting period (December 31, 2016 up to and including December 27, 2019) based on total return of shareholders against a defined peer group. The actual number of PSUs will be determined on the Grant Date by taking the dollar value allocated to PSUs and dividing such amount by the grant date fair value of a PSU using, for 50% of the value, a Monte Carlo simulation model and for the remaining 50% of the value, the closing price of the Companys ordinary shares on the Grant Date. Depending on the Companys performance during the performance period, the named executive officer is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0% to 200%, of the award granted.

50% of the target grant date fair value will be allocated to non-qualified stock options vesting in full on the fourth anniversary of the Grant Date. The actual number of stock options will be determined on the Grant Date by taking the dollar value allocated to stock options and dividing such amount by the grant date fair value of an option using a Black-Scholes valuation model.

The PSU, RSU and non-qualified stock option awards will be made pursuant to the terms and conditions of the Mallinckrodt Pharmaceuticals Stock and Incentive Plan and pursuant to the terms and conditions of the applicable award agreements.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MALLINCKRODT PUBLIC LIMITED COMPANY

Date:

November 22, 2016

By:

/s/ Kenneth L. Wagner

Kenneth L. Wagner

Vice President and Corporate Secretary

makes a similar move, sign up!

Other recent filings from the company include the following:

Tender offer statement by Third Party - Nov. 16, 2017
Mallinckrodt Plc's Chief HR Officer just picked up 2,000 shares - Nov. 15, 2017
Exec. VP & Pres of Mallinckrodt Plc just picked up 9,000 shares - Nov. 15, 2017
Mallinckrodt Plc director just picked up 5,000 shares - Nov. 13, 2017
Mallinckrodt Plc director just picked up 10,000 shares - Nov. 13, 2017

Auto Refresh

Feedback